1Y Target$833.31Near-term target
5Y Target$1,029Compound horizon
10Y Target$1,512Long-dated conviction
FCF$3.8bTTM · 03/26BFCF $3.8b — solid, comfortably covers operations and capital return · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+19.0%TTM YoYB+Revenue +19.0% — above sector median, healthy trajectory
D/E0.09AD/E 0.09 — essentially debt-free, pristine balance sheet
P/E15.6xB+P/E 15.6 — at or below S&P median, reasonable
PEG1.11B+PEG 1.11 — near fair value, classic Lynch benchmark (1.0)
Why now
Biotechnology · market cap $67.0b. Down 22% from 52-week high of $821.11 — deep drawdown territory. Revenue growing +19%, comfortably above the S&P median. 28 sell-side analysts rate this a Buy with a mean 1-yr target of $833.31 (implying +30% upside).
Moat
Net margin 30% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 15% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. $67.0b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $833.31 (28-analyst consensus) — fundamentals + valuation re-rating. 5 yr $1,029 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $1,512 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.